300199.SZ
Hybio Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 23.14
−0.26%Year over year
Reported trailing growth
- Revenue
- +27.4%
- EBITDA
- —
- EBIT
- +262.4%
- EPS
- +197.7%
- Free cash flow
- —
- Operating cash flow
- +38.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +11.1%
- EBITDA
- +1935.3%
- EBIT
- +142.8%
- Net income
- +121.1%
- EPS
- +120.0%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026